20 articles
A Phase 2 trial tests once-daily oral resmetirom (MGL-3196) against placebo to reduce LDL-C in patients with inherited high cholesterol.
A new review examines how drugs that clear senescent cells could transform treatment of age-related cardiovascular disease.
A landmark Phase 3 trial evaluates whether omecamtiv mecarbil, a cardiac myosin activator, reduces cardiovascular death in HFrEF patients.
Natural isoflavone prevents cardiac enlargement through novel mitochondrial protection pathway, offering new therapeutic approach.
A completed registry study identified and genotyped HoFH patients with LDLR mutations, laying groundwork for targeted gene therapy.
New study shows clearing senescent cells with Navitoclax improves heart function and reduces inflammation in heart failure with preserved ejection fraction.
Leading cardiac researchers challenge LVNC as a valid diagnosis, arguing the morphological pattern is a flawed basis for clinical decision-making.
New genetic approach could revolutionize how we develop heart medications, potentially saving billions in failed drug trials.
Scientists discover how an unusual gene fusion in melanoma still drives cancer growth and responds to targeted treatment.
New research identifies unique molecular signatures in gut lymph and blood that could transform digestive health monitoring.
Revolutionary nanobody drug targets two proteins simultaneously, achieving complete tumor elimination in preclinical studies.
Researchers created the first comprehensive atlas of bone metastases, revealing new immune therapy combinations that could help patients.
Myqorzo (aficamten) wins FDA approval for symptomatic obstructive HCM, offering a novel cardiac myosin inhibitor option for patients.
New framework proposes treating interconnected organ diseases together rather than separately for better outcomes.
A completed Phase 3 RCT examines whether weekly semaglutide injections improve symptoms and body weight in heart failure patients with obesity.
Scientists discover targeting two cellular pathways simultaneously could overcome treatment resistance in neuroendocrine tumors.
The first disease-specific treatment for Barth syndrome gains FDA accelerated approval, targeting mitochondrial dysfunction to restore muscle strength.
New research reveals how obesity-driven cellular senescence creates a toxic environment that fuels breast cancer development and progression.
A phase 1 trial tests RBD7022, a novel subcutaneous RNA-based therapy, for safety and dosing in adults with high LDL cholesterol.
Machine learning model identifies HFpEF patients 6.3 years before symptom onset with 93% accuracy using integrated clinical and molecular data.
